Meizhou

Researchers are studying patritumab deruxtecan (MK-1022) as a treatment for certain advanced gastrointestinal cancers, including colorectal cancer, biliary tract cancer, hepatocellular carcinoma, and gastroesophageal cancer. These cancers have spread or cannot be surgically removed. The study aims to understand the safety, tolerability, and effectiveness of this treatment, especially how many patients experience tumor shrinkage or disappearance. Participants will receive patritumab deruxtecan through intravenous infusion. The study includes both Phase 1 and Phase 2 stages to evaluate safety and how well the treatment works. Patients who have already undergone prior therapy for their cancer and have recovered from any side effects will be enrolled. During the study, researchers will monitor participants for dose-limiting toxicities within 21 days, track any adverse events over about 44 months, and observe if participants stop treatment due to side effects. The main outcome also includes measuring the objective response rate, or how many patients' tumors respond to the treatment. Safety and efficacy will be carefully assessed throughout the trial.